Andrew Worland – Managing Director and Chief Executive Officer – International Graphite (ASX:IG6) is building Australia’s capability in critical battery minerals and establishing a new ethical supply of battery anode graphite to support the global revolution in clean energy.
Copyright 2023 – Finance News Network
12 Apr 2023 - eCargo Holdings Limited (ASX:ECG) Group CEO Lawrence Lun discusses recent results, strategy, opportunities post lockdown and milestones ahead.
22 Mar 2022 - Magnetite Mines Limited (ASX:MGT) Technical Director Mark Eames discusses the business case for further expansion of the Razorback Iron Ore Project in South Australia from three million tonnes per annum to seven million tonnes per annum.
30 Jul 2024 - Joe David - CEO - Elementos (ASX:ELT) is committed to the safe and environmentally conscious exploration, development, and production of its global tin projects. The company owns two world class tin projects with large resource bases and significant exploration potential in mining-friendly jurisdictions.
09 Mar 2021 - Paragon Care Limited (ASX:PGC) CEO Phil Nicholl provides an update on the company's 1H21 results, discussing the increase in elective surgery and higher margin sales following COVID disruptions.
23 Dec 2019 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO, James McBrayer talks about the company's joint venture to expand Positron Emission Tomography (PET) diagnostics business opportunities for NSW and Australia.
07 Oct 2022 - Stealth Global Holdings Limited (ASX:SGI) Group Managing Director Michael Arnold discusses the business offering, M&A activity, clients, 2025 strategy and financial targets.
28 Feb 2024 - Oliver Kiddie - Managing Director - Legend Mining is an Australian exploration company listed on the Australian Securities Exchange (ASX:LEG). Legend’s mission is to make value-adding mineral discoveries and utilise all available asset bases to maximise stakeholder benefit.
30 Nov 2021 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow talks about the recent presentation of data from the CHM 1101 (Chlorotoxin CAR T) Phase 1 clinical trial in glioblastoma patients.
